

BEST AVAILABLE COPY

BB



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/53, 33/566, C07K 14/435, 19/00, C12N 15/12	A1	(11) International Publication Number: WO 99/31508 (43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/US98/26457 (22) International Filing Date: 11 December 1998 (11.12.98) (30) Priority Data: 60/069,747 16 December 1997 (16.12.97) US (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FONG, Tung, Ming [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). VAN DER PLOEG, Leonardus, H., T. [NL/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). TOTA, Michael, R. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: C-TERMINAL REGION OF AGOUTI-RELATED TRANSCRIPT (ART) PROTEIN		
(57) Abstract Novel polypeptides derived from the C-terminal region of the human and mouse agouti related transcript (ART) proteins are provided. Also provided are DNA sequences encoding the novel C-terminal polypeptides. The novel C-terminal polypeptides can be used to inhibit the binding of melanocyte stimulating hormones to melanocortin receptors. Methods of identifying inhibitors of the binding of ART protein to melanocortin receptors are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 99/31508

PCT/US98/26457

TITLE OF THE INVENTION**C-TERMINAL REGION OF AGOUTI-RELATED TRANSCRIPT (ART)
PROTEIN****5 CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of U.S. Provisional Application No. 60/069,747, filed December 16, 1997, the contents of which are incorporated herein by reference in their entirety.

10 STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable

REFERENCE TO MICROFICHE APPENDIX

Not applicable

15**FIELD OF THE INVENTION**

The present invention is directed to polypeptides derived from the C-terminal region of the agouti-related transcript (ART) protein and to uses of such polypeptides, including use as inhibitors of the binding of melanocyte stimulating hormones to melanocortin receptors, and use to identify inhibitors of the binding of ART protein to melanocortin receptors.

20**BACKGROUND OF THE INVENTION****25**

ART (agouti related transcript) was originally discovered as an mRNA that is upregulated in the hypothalamus of ob/ob and db/db mice. The ART gene has been cloned from both mice and humans and encodes a protein of 131 amino acids in mice and 132 amino acids in humans (Shutter *et al.*, 1997, Genes and Development 11:593-602).

30

Recombinantly produced ART protein has been shown to be a functional antagonist of the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R) (Fong *et al.*, 1997, Biochem. Biophys. Res. Comm. 237:629-631; Ollman *et al.*, 1997, Science 278:135-138).

35

MC3R and MC4R belong to a class of G-protein coupled receptors known as the melanocortin receptors, since these receptors activate adenylyl cyclase in response to ligands known as melanocortins (e.g., adrenocorticotrophin (ACTH) and the α -, β -, and γ -melanocyte

- WO 99/31508

PCT/US98/26457

2

stimulating hormones). MC3R and MC4R are neural melanocortin receptors, with MC3R being expressed in the hypothalamus and limbic system of the brain and MC4R being expressed widely in the brain. In particular, MC4R expression has been found in a number of
5 hypothalamic sites, including the ventromedial, lateral, dorsomedial, and paraventricular nuclei (Mountjoy *et al.*, 1994; Mol. Endocrinol. 8:1298-1308), regions which have been shown to play a role in feeding behavior (Bray, 1987, Nutr. Rev. 45:33-43). Gene targeting experiments have shown that MC4R has an important role in the control of feeding
10 behavior and obesity. Knockout mice lacking MC4R develop an obesity syndrome characterized by hyperphagia, hyperinsulinemia, and hyperglycemia (Huszar *et al.*, 1997, Cell 88:131-141).

In view of this, there is great interest in the ART protein, which appears to be a natural regulator of MC3R and MC4R in humans.
15 It is believed that the ART protein is likely to be a natural regulator of human obesity which functions by antagonizing either MC3R or MC4R. Accordingly, the identification of substances that inhibit the binding of ART protein to MC3R or MC4R is desirable, since such inhibitors are likely to be of value in the control of obesity. Substances that potentiate
20 the effect of ART protein on MC3R or MC4R are also likely to be of value in the control of body weight.

SUMMARY OF THE INVENTION

The present invention provides novel polypeptides derived
25 from the C-terminal region of the human and mouse ART proteins. Also provided are DNA sequences encoding the novel C-terminal polypeptides. The novel C-terminal polypeptides can be used to inhibit the binding of melanocyte stimulating hormones to melanocortin receptors. Methods of identifying inhibitors of the effect of ART protein
30 on the binding of melanocyte stimulating hormones to melanocortin receptors are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the quantitation of c-ART-b from COS-7 cells
35 through the use of an ELISA using an antibody that recognizes the myc epitope in c-ART-b. Shown is the standard curve generated using known amounts of myc peptide. For the c-ART-b preparation made

WO 99/31508

PCT/US98/26457

3

from COS-7 cells, a 10x dilution of the sample gave an absorbance of 0.079, corresponding to 10 nM in the above standard curve. Therefore, the c-ART-b preparation had a concentration of 100 nM.

Figure 2 shows the binding affinity of c-ART-b for the human MC3R. Shown is the inhibition of ^{125}I -[Tyr²][Nle⁴, D-Phe⁷] α -melanocyte stimulating hormone (^{125}I -NDP- α -MSH) binding to the human MC3R by c-ART-b.

Figure 3 shows the binding affinity of c-ART-b for the human MC4R. Shown is the inhibition of ^{125}I -NDP- α -MSH binding to the human MC4R by c-ART-b.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides C-terminal polypeptides derived from the agouti-related transcript (ART) protein and DNA sequences encoding those polypeptides. The C-terminal polypeptides from the ART protein are referred to herein as "ART polypeptides". In certain embodiments, the ART polypeptides are present in a contiguous polypeptide sequence, *i.e.*, a fusion protein, that incorporates, generally at the C-terminus of the fusion protein, one or more amino acid sequences not derived from the ART protein. Such non-ART protein sequences can be, *e.g.*, "tags", such as a protein kinase A site (for easier radioisotope labeling) or an antigenic sequence (*e.g.*, a myc epitope) for ELISA quantitation. Other tags are known in the art and ART polypeptides incorporating such other tags are included in the present invention. In other embodiments, the ART polypeptides are present in a fusion protein with another protein that gives rise to an easily detectable signal, *e.g.*, alkaline phosphatase (ART-AP) or luciferase (ART-luc). Fusion proteins such as ART-AP or ART-luc are useful in binding assays since their presence and/or concentration can be detected without the use of radioactivity.

In particular, the present invention includes the following ART polypeptides:

c-ART-a: This polypeptide contains, from N to C terminus: (1) a yeast signal sequence peptide; (2) amino acids 76-132 of the human ART protein; (3) a thrombin site; (4) a myc epitope; (5) a

- WO 99/31508

PCT/US98/26457

4

protein kinase A (PKA) site; and (6) a hexahistidine tag. The amino acid sequence of c-ART-a is:

MNIFYIFLFLLSFVQGLEHTRRGSLVKRSSLQDREPRS

5

1

SRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLG

2

TAMNPCSRTLVPRGSEQKLISEEDLNLRASLGHHHHHH

3

4

5

6

10 (SEQ.ID.NO.:1)

c-ART-b: This polypeptide contains, from N to C terminus: (1) amino acids 1-26 of the human ART protein; (2) amino acids 76-132 of the human ART protein; (3) a thrombin site; (4) a myc epitope; and (5) a hexahistidine tag. The amino acid sequence of c-ART-b is:

MLTAALLSCALLLALPATRGAQMGLALQDREPRSSRRCVRL

1

20 HESCLGQQVPCCDPCATCYCRFFNAFCYCRKLG TAMNPCS

2

RTLVPRGSGSELGTLGPEQKLISEEDLNSAVDHHHHHH

3

4

5

(SEQ.ID.NO.:2)

25

c-ART-c: This polypeptide contains, from N to C terminus: (1) amino acids 1-26 of the human ART protein; (2) amino acids 76-132 of the human ART protein; (3) a thrombin site; (4) a PKA site; (5) a myc epitope; and (6) a hexahistidine tag. The amino acid sequence of c-ART-c is:

30

WO 99/31508

PCT/US98/26457

5

MLTAALLSCALLLALPATRGAQMGLALQDREPRSSRRCVRL

1

HESCLGQQVPCCDPCATCYCRFFNAFCYCRKLG TAMNPCSRT

2

5 LVPRGSGSLRRASLGKLEQKLISEEDLNSAVDHHHHHH

3

4

5

6

(SEQ.ID.NO.:3)

10 ART-AP: This polypeptide contains, from N to C terminus: (1) amino acids 1-132 of the human ART protein; (2) a thrombin site; (3) the alkaline phosphatase protein; (4) a myc epitope; and (5) a hexahistidine tag. The amino acid sequence of ART-AP is:

MLTAALLSCALLLALPATRGAQMGLAPMEGIRRPDQALLP

15

ELPGLGLRAPLKKTNAEQAEEDLLQEAQALAEVLDLQDRE

1

PRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCR20 KLG TAMNPCSRTL VPRGSGSIIPVEEENPDFWNRQAAEAL

2

GAACKLQPAQTAAKNLIIFLGDGMGVSTVTAARILKGQKKDKLGPETFLAMDRFPYVALSKTYSVDKHVPD SGATATAYL

25

CGVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAGKSVG VVTTRVQHASPAGAYAHTVNRNWYSDADVPASA30 RQEGCQDIATQLISNMDIDVILGGGRKYMFPMTDPDEYPDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTELMQASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTE

35

3

AALRLLSRNPRGFFLFVEGGRIDHGHESRAYRALTETIM

WO 99/31508

PCT/US98/26457

6

FDDAIERAGQLTSEEDTSLVLTADHSHVSEFGGYPLRGSSIFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTES5 ESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHGVQEQTFIAHVMAFAACLEPYTACDLAPSAGTTDAAHPGKLGPEQKLISEEDLNSAVDHHHHHH (SEQ.ID.NO.:4)

10

4

5

ART-luc: This polypeptide contains, from N to C terminus: (1) amino acids 1-132 of the human ART protein; (2) a thrombin site; (3) the luciferase protein; (4) a myc epitope; and (5) a hexahistidine tag. The amino acid sequence of ART-luc is:

15

MLTAALLSCALLLALPATRGAQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKTNAEQAEEDLLQEAQALAEVLDLQDRE

20

1

PRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSRTLVPRGSGSMSIENNILIGPPPYYPLEEG

2

25 TAGEQLHRAISRYAAVPGTLAYTDVHTELEVITYKEFLDVTCRLAEAMKNYGLGLQHTISVCSENCVQFFMPICAALYVGVATAPTNDIYNERELYNLSISQPTVVFTSRNSLQKILGVQ

30

SRLPIKKKIILDGKKDYLGYQSMQSFEMKEHVPANFNVSAFKPLSFDLDRVACIMNSSGSTGLPKGVPISHRNTIYRFSH35 CRDPVFGNQIIPDTILCAVPFHHAFGTFTNLGYLICGFH

- WO 99/31508

PCT/US98/26457

7

VVLMYRFNEHLFLQTLQDYKCQSALLVPTVLAFLAKNPL

3

VDKYDLSNLHEIASGGAPLSKEISEIAAKRFKLPGIRQGYG5 LTETTCaIVITAEGEFKLGAvgkvVpFYSLKVLDLNTGKKLGPNERGEICFKGPMIMKGYINNPEATRELIDEEGWIHSGDIGYFDEDGHVYIVDRLKSLIKYKGYQVPPAELEALLQH

10

PFIEDAGVAGVPDEVAGDLPGAVVVLKEGKSITEKEIQDYVAGQVTSSKKLRGGVEFVKEVPKGFTGKIDTRKIKEILIK15 AQKGKSKSAKLGPEQKLISEEDLNSAVDHHHHHH (SEQ.ID.NO.:5)

4

5

20 The present invention also includes an ART polypeptide
containing amino acids 1-26 and 76-132 of the human ART protein,
having the following polypeptide sequence:

MLTAALLSCALLLALPATRGAQMGLALQDREPRSSRRCVRL
HESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSRT
(SEQ.ID.NO.:6)

25

The present invention also includes an ART polypeptide
containing amino acids 76-132 of the human ART protein, having the
following polypeptide sequence:

30 LQDREPRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKL
GTAMNPCSRT (SEQ.ID.NO.:7)

35 The present invention also includes an ART polypeptide
containing amino acids 1-26 and 75-131 of the mouse ART protein,
having the following polypeptide sequence:

PCT/US98/26457

MLTAMLLSCVLLLLALPPTLGVQMGGVAPQNRERSRRCVRL
HESCLGQQVPCCDPCATCYCRFFNAFCYCRKLG TAMNLC SRT
(SEQ.ID.NO.:8)

10 PQNRESRSPRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGT
AMNLC SRT (SEQ.ID.NO.:9)

MNIFYIFLFLSFVQGLEHTRRGLVKRSSPQNRESRSPRRCVRL

LVPRGSEQKLISEEDLNLRASLGHHHHH (SEQ.ID.NO.:10)

30
MLTAMLLSCVLLALPPTLGVMGVAPQNRESRSPRRCVRL

HESCLGQQVPCCDPCATCYCRFFNAFCYCRKLG TAMNLC SRT

LVPRGSEQKLISEEDLNLRRASLSHHHHHH (SEQ.ID.NO.:11)

WO 99/31508

PCT/US98/26457

9

The present invention also includes an ART polypeptide having the following sequence, from N to C terminus: (1) amino acids 1-26 of the mouse ART protein; (2) amino acids 75-131 of the mouse ART protein; (3) a thrombin site; (4) PKA site; (5) a myc epitope; and (6) a hexahistidine tag. The amino acid sequence of this ART polypeptide is:

MLTAMLLSCVLLLLALPPTLGVQMGVAPQNRESRSPRRCVRL
1
HESCLGQQVPCCDPCATCYCRFFNAFCYCRKLG
TAMNLC
SRT
2
3 4 5 6
LVPRGSGSLRRASLGKLEQKLISEEDLNHHHHHH
(SEQ.ID.NO.:12)

The present invention also includes an ART polypeptide, having the following sequence, from N to C terminus: (1) amino acids 1-131 of the mouse ART protein; and (2) the alkaline phosphatase protein. The amino acid sequence of this polypeptide is:

MLTAMLLSCVLLLLALPPTLGVQMGVAPLKGIRRPDQAL
FP EFPGLSLNGLKKTNADRAEEVLLQKAEALAEVLDP
1
QNRESRSPRRCVRLHESCLGQQVPCCDPCATCYCRFFN
25 AFCYCRKLGTAMNLCSRTIIPVEEENPDFWNRQAAEAL
GAAKKLQPAQTAAKNLIIFLGDGMGVSTVTAARILKGQKK
30 DKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYL
CGVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAG
KSVGVVTTTRVQHASPAGAYAHTVNRNWYSDADVPASA
35 RQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEY

WO 99/31508

PCT/US98/26457

10

PDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTELM

QASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTE

2

5 AALRLLSRNPRGFFLFVEGGRIDHGHESRAYRALTETIM

FDDAIERAGQLTSEEDTSLVTADHSHVFSFGGYPLRGSS

10 IFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTES

ESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHG

VQEQTFLAHVMAFAACLEPYTACDLAPSAGTTDAAHPG

15 (SEQ.ID.NO.:13)

The present invention also includes an ART polypeptide, having the following sequence, from N to C terminus: (1) amino acids 1-131 of the mouse ART protein; and (2) the luciferase protein. The amino acid sequence of this polypeptide is:

20

MLTAMLLSCVLLLALPPTLGVQMGVAPLKGIRRPDQALFPEFPGLSLNGLKKTNADRAEEVLLQKAEALAEVLDPQNRRES

25

1

RSPRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNLCsRTMSIENNILIGPPPYYPLEEGTAGEQLHR

30 AISRYAAVPGTLAYTDVHTELEVITYKEFLDVTCLAEAE

MKNYGLGLQHTISVCSENCVQFFMPICAALYVGVATAP

TNDIYNERELYNSLSISQPTVVFTSRNSLQKILGVQSR

35

LPIIKKIIILDGKKDYLGYQSMQSFMKEHVPANFNVSA

WO 99/31508

PCT/US98/26457

11

FKPLSFDLDRVACIMNSSGSTGLPKGVPIHRNTIYRFSH
CRDPVFGNQIIPDTTILCAVPFHHAFGTFTNLGYLICGFH
5 VVLMYRFNEHLFLQTLQDYKCQSALLVPTVLAFLAKNPL
2
VDKYDLSNLHEIASGGAPLSKEISEIAAKRFKLPGIRQGYG
LTETTCAIVITAEGEFKLGAVGKVVPFYSLKVLDLNTGKK
10 LGPNERGEICFKGPMIMKGYINNPEATRELIDEEGWIHSG
DIGYFDEDGHVYIVDRLKSLIKYKGYQVPPAELEALLQH
15 PFIEDAGVAGVPDEVAGDLPGAVVVLKEGKSITEKEIQDY
VAGQVTSSKKLRGGVEFVKEVPKGFTGKIDTRKIKEILIK
AQKGKSKSKAKL (SEQ.ID.NO.:14)

20

The present invention also includes an ART polypeptide, having the following sequence, from N to C terminus: (1) amino acids 1-26 of the human ART protein; (2) amino acids 76-132 of the human ART protein; (3) a thrombin site; (4) the alkaline phosphatase protein; (5) a myc epitope; and (6) a hexahistidine tag. The amino acid sequence of this polypeptide is:

MLTAALLSCALLLALPATRGAQMGLALQDREPRSSRRCV
1
30 RLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTA
2
MNPCSRTLVPRGSGSIIPVEEENPDFWNRQAAEAL
3
GAAKKLQPAQTAAKNLIIFLGDMGVSTVTAARILKGQKK
35 DKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYL

WO 99/31508

PCT/US98/26457

12

CGVKGNFQTIGLSAAARFNQCNTRGNEVISVMNRAKKAG
KSVGVTTRVQHASPAGAYAHTVNRNWYSDADVPASA
5 RQEGCQDIATQLISNMDIDVILGGGRKYMFPMPGTPDPEY
PDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTLM
QASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTE
10 AALRLLSRNPRGFFLFVEGGRIDHGHESRAYRALTETIM
FDDAIERAGQLTSEEDTSLSLVTADHSHVFSFGGYPLRGSS
15 IFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTES
ESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHG
VQEQTFAHVMAFAACLEPYTACDLAPSAGTTDAAHPG
20 KLGPEQKLISEEDLNSAVDHHHHHH (SEQ.ID.NO.:15)

5

6

The present invention also includes an ART polypeptide,
25 having the following sequence, from N to C terminus, (1) amino acids 1-
26 of the human ART protein; (2) amino acids 76-132 of the human ART
protein; (3) a thrombin site; (4) the luciferase protein; (5) a myc epitope;
and (6) a hexahistidine tag. The amino acid sequence of this polypeptide
is:

30

MLTAALLSCALLLALPATRGAQMGLALQDREPRSSRRC

1

VRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTA

2

35 MNPCSRTLVPRGSGSMSIENNILIGPPPYPLEEGTAGEQLHR

3

AISRYAAVPGTLAYTDVHTELEVITYKEFLDVTCLAEA

WO 99/31508

PCT/US98/26457

13

MKNYGLGLQHTISVCSENCVQFFMPICAALYVGVATAP
TNDIYNERELYNSLSISQPTVVFTSRNSLQKILGVQSR
5 LPIIKKIIILDGKKDYLGYSMQSFMKEHVPANFNVSA
FKPLSFDLDRVACIMNSSGSTGLPKGVPISHRNTIYRFSH
10 CRDPVFGNQIIPDTTILCAVPFHHAFTFTNLGYLICGFH
VVLMYRFNEHLFLQTLQDYKCQSALLVPTVLAFLAKNPL
4
VDKYDLSNLHEIASGGAPLSKEISEIAAKRFKLPGIRQGYG
15 LTETTCAIVITAEGEFKLGAVGKVVPFYSLKVLDLNTGKK
LGPNERGEICFKGPMIMKGYINNPEATRELIDEEGWIHSG
20 DIGYFDEDGHVYIVDRLKSLIKYKGYQVPPAELEALLQH
PFIEDAGVAGVPDEVAGDLPGAVVVLKEGKSITEKEIQDY
VAGQVTSSKKLRGGVEFVKEVPKGFTGKIDTRKIKEILIK
25 AQKGKSKSKAKLGPEQKLISEEDLNSAVDHHHHHH (SEQ.ID.NO.:16)
5 6

30 The present invention also includes an ART polypeptide
having the following sequence, from N to C terminus: (1) amino acids 1-
132 of the human ART protein; and (2) the alkaline phosphatase protein.
The amino acid sequence of this polypeptide is:

35 MLTAALLSCALLLALPATRGAQMGLAPMEGIRRPDQALLP
ELPGLGLRAPLKKTNAEQAEEDLLQEAQALAEVLDLQDRE

WO 99/31508

PCT/US98/26457

14

PRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSRTIIPVEEENPDFWNRQAAEALGAAKKLQPA

5 QTAAKNLIIFLGDGMGVSTVTAARILKGQKKDKLGPETF

LAMDRFPYVALSKTYSVDKHVPDSGATATAYLCGVKGN

10 FQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAGKSVG

VVTTRVQHASPAGAYAHTVNRNWYSDADVPSARQ

EGCQDIATQLISNMDIDVILGGGRKYMFPMPGTPDPEY

15 PDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTELM

QASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTE

2

20 AALRLLSRNPRGFFLFVEGGRIDHGHHSRAYRALTETIM

FDDAIERAGQLTSEEDTSLSLVTADHSHVFSFGGYPLRGSS

IFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTE

25 ESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHG

VQEQTFIAHVMAFAACLEPYTACDLAPSAGTTDAAHPG

(SEQ.ID.NO.:17)

30

The present invention also includes an ART polypeptide having the following sequence, from N to C terminus: (1) amino acids 1-132 of the human ART protein; and (2) the luciferase protein. The amino acid sequence of this polypeptide is:

35

WO 99/31508

PCT/US98/26457

15

MLTAALLSCALLALPATRGAQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKTNAEQAEEDLLQEAQALAEVLDLQDRE

1

5 PRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSRTMSIENNILIGPPPYYPLEEGTAGEQLH

RAISRYAAVPGTLAYTDVHTELEVITYKEFLDVTCLAE

10

AMKNYGLGLQHTISVCSENCVQFFMPICAALYVGVAT

APTNDIYNERELYNSLSISQPTVVFTSRNSLQKILGVQ

15 SRLPIIKKIIILDGKKDYLGYQSMQSFMKEHVPANFNVSA

FKPLSFDLDRVACIMNSSGSTGLPKGVPISHRNTIYRFSH

CRDPVFGNQIIPD TTILCAVPFHHAFTFTNLGYLICGFH

20

VVLMYRFNEHLFLQTLQDYKCQSALLVPTVLAFLAKNPL

2

VDKYDLSNLHEIASGGAPLSKEISEIAAKRFKLPGIRQGYG

25 LTETTCAIVITAEGEFKLGAVGKVVPFYSLKVLDLNTGKK

LGPNERGEICFKGPMIMKGYINNPEATRELIDEEGWIHSG

DIGYFDEDGHVYIVDRLKSLIKYKGYQVPPAELEALLQH

30

PFIEDAGVAGVPDEVAGDLPGAVVVLKEGKSITEKEIQDY

VAGQVTSSKKLRGGVEFVKEVPKGFTGKIDTRKIKEILIK

35 AQKGKSKSKAKL (SEQ.ID.NO.:18)

WO 99/31508

PCT/US98/26457

16

The present invention also includes an ART polypeptide having the following sequence, from N to C terminus: (1) amino acids 1-26 of the human ART protein; (2) the alkaline phosphatase protein; (3) amino acids 27-132 of the human ART protein. The amino acid sequence is:

MLTAALLSCALLLALPATRGAQMGLAIPVEEENPDFWNRQAAEAL

1

GAAKKLQPAQTAAKNLIIFLGDMGVSTVTAARILKGQKK

DKLGPETFLAMDRFPYVALSKTYSVDKHVPDSGATATAYL

CGVKGNFQTIGLSAAARFNQCNTTRGNEVISVMNRAKKAG

KSVGVTTTTRVQHASPAGAYAHTVNRNWYSDADVPASA

RQEGCQDIATQLISNMDIDVILGGGRKYMFFPMGTPDPEY

PDDYSQGGTRLDGKNLVQEWLAKHQGARYVWNRTELM

QASLDPSVTHLMGLFEPGDMKYEIHRDSTLDPSLMEMTE

2

AALRLLSRNPRGFFLFVEGGRIDHGHESRAYRALTETIM

FDDAIERAGQLTSEEDTLSTADHSHVFSFGGYPLRGSS

IFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTES

ESGSPEYRQQSAVPLDGETHAGEDVAVFARGPQAHLVHG

VQEQTFIAHVMAFAACLEPYTACDLAPSAGTTDAAHPG

PMEGIRRPDQALLPELPGLGLRAPLKKTNAEQAEEDLLQE

3

AQALAEVLDLQDREPRSSRRCVRLHESCLGQQVPCCDPC

ATCYCRFFNAFCYCRKLGTMNPCSRT (SEQ.ID.NO.:19)

WO 99/31508

PCT/US98/26457

17

The present invention also includes an ART polypeptide having the following sequence, from N to C terminus: (1) amino acids 1-26 of the human ART protein; (2) the luciferase protein; (3) amino acids 27-132 of the human ART protein. The amino acid sequence is:

MLTAALLSCALLALPATRGAQMGLAMSIENNILIGPPPYPLEEG
1
TAGEQLHRAISRYAAVPGTLAYTDVHTELEVITYKEFLDVT
10 CRLAEAMKNYGLGLQHTISVCSENCVQFFMPICAALYVG
VATAPTNDIYNERELYNLSISQPTVVFTSRNSLQKILGVQ
15 SRLPIIKKIIILDGKKDYLGYQSMQSFMKEHVPANFNVSA
FKPLSFDLDRVACIMNSSGSTGLPKGVPISHRNTIYRFSH
CRDPVFGNQIIPD TTILCAVPFHHAFGTFTNLGYLICGFH
20 VVLMYRFNEHLFLQTLQDYKCQSALLVPTVLAFLAKNPL
2 VDKYDLSNLHEIASGGAPLSKEISEIAAKRFKLPGIRQGYG
25 LTETTCAIVITAEGEFKLGAVGKVVPFYSLKVLDLNTGKK
LGPNERGEICFKGPMIMKGYINNPEATRELIDEEGWIHSG
DIGYFDEDGHVYIVDRLKSLIKYKGYQVPPAELEALLQH
30 PFIEDAGVAGVPDEVAGDLP GAVVVLKEGKSITEKEIQDY
VAGQVTSSKKLRGGVEFVKEVPKGFTGKIDTRKIKEILIK
35 AQKGKSKSKAKLPMEGIRRPDQALLPELPGLGLRAPLKK

WO 99/31508

PCT/US98/26457

18

TNAEQAEEDLLQEAQALAEVLDLQDREPRSSRRCVRLHE

3

SCLGQQVPCCDPCATCYCRFFNAFCYCRKLG TAMNPCSRT

5 (SEQ.ID.NO.:20)

The ART polypeptides of the present invention can be in a form that is substantially free from other polypeptides. "Substantially free from other polypeptides" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins. Thus, an ART polypeptide preparation that is substantially free from other polypeptides will contain, as a percent of its total polypeptides, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-ART polypeptides. Whether a given ART polypeptide preparation is substantially free from other polypeptides can be determined by such conventional techniques as, e.g., sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate staining methods, e.g., silver staining.

It is possible to modify many of the amino acids of the ART polypeptides of the present invention and still retain substantially the same biological activity as possessed by the unmodified ART polypeptide. A modified ART polypeptide has "substantially the same biological activity" as an unmodified ART polypeptide if the modified polypeptide has an IC₅₀ value for the inhibition of ¹²⁵I-labeled NDP- α -MSH binding to MC3R or MC4R that is no more than 5-fold greater than the IC₅₀ value of the unmodified ART polypeptide for the inhibition of ¹²⁵I-labeled NDP- α -MSH binding to MC3R or MC4R.

Thus the present invention includes modified ART polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as the unmodified ART polypeptide from which they are derived. It is generally accepted that single amino acid substitutions at non-critical positions do not usually alter the biological activity of a protein or polypeptide (see, e.g., Molecular Biology of the Gene, Watson *et al.*, 1987, Fourth Ed., The Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham & Wells, 1989, Science 244:1081-1085). Accordingly,

WO 99/31508

PCT/US98/26457

19

the present invention includes modified polypeptides where one amino acid substitution has been made in SEQ.ID.NOs.:1-20 wherein the modified polypeptides still retain substantially the same biological activity as the unmodified ART polypeptides. The present invention also includes modified polypeptides where two amino acid substitutions have been made in SEQ.ID.NOs.:1-20 wherein the polypeptides still retain substantially the same biological activity as the unmodified ART polypeptides. More generally, the present invention includes modified polypeptides where amino acid substitutions have been made in regions of the polypeptides that are not critical, *i.e.*, in regions where modifications result in a polypeptide with substantially the same biological activity as the unmodified polypeptide.

In particular, the present invention includes embodiments where the above-described substitutions are conservative substitutions. A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (*e.g.*, arginine for lysine; glutamic acid for aspartic acid).

The present invention also includes DNA sequences encoding polypeptides having the amino acid sequences of SEQ.ID.NOs.:1-20, with the proviso that, In the case of the DNA sequences encoding SEQ.ID.NOs.:6-9, the DNA sequences do not encode any contiguous stretch of amino acids from the ART protein other than SEQ.ID.NOs.:6-9.

The DNA sequences of the present invention can be in a form that is substantially free from other nucleic acids. "Substantially free from other nucleic acids" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. Thus, a preparation of DNA sequences encoding an ART polypeptide that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acids, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of nucleic acids other than the DNA sequences encoding ART polypeptides. Whether a given preparation of

WO 99/31508

PCT/US98/26457

20

DNA sequences encoding an ART polypeptide is substantially free from other nucleic acids can be determined by such conventional techniques as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining.

5 The DNA sequences of the present invention encoding ART polypeptides can be linked with other DNA sequences, *e.g.*, DNA sequences to which DNA sequences encoding the ART protein are not naturally linked, to form "recombinant DNA molecules" encoding ART polypeptides. Such other sequences can include DNA sequences that
10 control transcription or translation such as, *e.g.*, translation initiation sequences, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer sequences, sequences that control replication in microorganisms, or that confer antibiotic resistance. The DNA sequences of the present invention can be inserted
15 into vectors such as plasmids, cosmids, viral vectors, or yeast artificial chromosomes.

 Included in the present invention are DNA sequences that hybridize to the DNA sequences encoding ART polypeptides under stringent conditions. By way of example and not limitation, a procedure
20 using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hr. to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured
25 salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography. Other procedures using conditions of high stringency would include either a hybridization carried out in
30 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

 Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art.
35 Details of the composition of these reagents can be found in, *e.g.*, Sambrook, Fritsch, and Maniatis, 1989, Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory

WO 99/31508

PCT/US98/26457

21

Press. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding ART polypeptides. Such recombinant host cells can be cultured under suitable conditions to produce ART polypeptides. An expression vector containing DNA encoding ART polypeptides can be used for expression of ART polypeptides in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which are suitable for recombinant expression of ART polypeptides and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).

A variety of mammalian expression vectors can be used to express ART polypeptides in mammalian cells. Commercially available mammalian expression vectors which are suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNAI and pcDNAIamp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), and pSV2-dhfr (ATCC 37146). Following expression in recombinant cells, ART polypeptides can be purified by conventional techniques to a level that is substantially free from other proteins.

The present invention includes a method of determining whether a substance is an inhibitor of the binding of an ART polypeptide to a melanocortin receptor. Such substances are likely to be useful in the control of body weight. The method takes advantage of the fact that ART polypeptides inhibit the binding of melanocyte stimulating hormones to melanocortin receptors by themselves binding to the receptor. Thus, a

WO 99/31508

PCT/US98/26457

22

substance that antagonizes the inhibitory effect of ART polypeptides on the binding of melanocyte stimulating hormones to melanocortin receptors is likely to act by inhibiting the binding of the ART polypeptide itself to the melanocortin receptor. The method comprises:

- 5 (a) providing cells expressing the melanocortin receptor;
- (b) exposing the cells to a chosen concentration of the melanocyte stimulating hormone in the absence of the ART polypeptide and in the absence of the substance and measuring the amount of melanocyte stimulating hormone binding to the cells to obtain a first
10 value for melanocyte stimulating hormone binding;
- (c) exposing the cells to the chosen concentration of melanocyte stimulating hormone in the presence of a chosen concentration of the ART polypeptide and in the absence of the substance and measuring the amount of melanocyte stimulating hormone binding
15 to obtain a second value for melanocyte stimulating hormone binding where the second value for melanocyte stimulating hormone binding indicates that less melanocyte stimulating hormone binding has occurred as compared to the first value for melanocyte stimulating hormone binding;
- 20 (d) exposing the cells to the chosen concentration of melanocyte stimulating hormone in the presence of the chosen concentration of ART polypeptide and in the presence of the substance and measuring the amount of melanocyte stimulating hormone binding to obtain a third value for melanocyte stimulating hormone binding;
- 25 where, if the third value for melanocyte stimulating hormone binding is greater than the second value, then the substance is an inhibitor of the binding of the ART polypeptide to the melanocortin receptor.

30 In a particular embodiment, the cells expressing the melanocortin receptor are cells that naturally express the melanocortin receptor. In another embodiment, the cells expressing the melanocortin receptor do not naturally express the melanocortin receptor but have been transfected with an expression vector that directs the expression of the melanocortin receptor. Transfection is meant to include any method
35 known in the art for the introduction of the the expression vector directing the expression of the melanocortin receptor into the cells. For example, transfection includes calcium phosphate or calcium chloride

WO 99/31508

PCT/US98/26457

23

mediated transfection, lipofection, infection with a retroviral construct containing the melanocortin receptor, and electroporation.

In a particular embodiment, the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R). In a particular embodiment of the above-described method, the melanocortin receptor is not a *Xenopus* melanocortin receptor.

The cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor can be prokaryotic cells or eukaryotic cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: yeast cells, mammalian cells, bacterial cells, and insect cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: human cells, mouse cells, rat cells, bovine cells, porcine cells, hamster cells, and monkey cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 cells (ATCC CRL 1573), Raji cells (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171). In a particular embodiment, the cells are not *Xenopus* melanophore cells.

In a particular embodiment, the melanocyte stimulating hormone is selected from the group consisting of: α -melanocyte stimulating hormone, β -melanocyte stimulating hormone, and γ -melanocyte stimulating hormone.

In a particular embodiment, the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs. 1-19 and 20.

In particular embodiments of the above-described method, the method is practiced *in vitro* and the conditions under which the method is practiced are conditions that are typically used in the art for

WO 99/31508

PCT/US98/26457

24

the study of protein-protein interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In particular embodiments of the above-described method,
5 the chosen concentration of the melanocyte stimulating hormone is from 0.05 nM to 2.0 nM, preferably from 0.1 nM to 1.0 nM, and more preferably from 0.2 nM to 0.5 nM.

In particular embodiments of the above-described method,
the chosen concentration of the ART polypeptide is from 10^{-12} M to
10 10^{-7} M.

In particular embodiments of the above-described method,
the method is practiced *in vitro* and the melanocyte stimulating
hormone is labeled, *e.g.*, enzymatically, radioactively, or the like, and
the amount of binding of the melanocyte stimulating hormone to the
15 melanocortin receptor is measured by determining the amount of label bound to the cells containing the melanocortin receptor.

Steps (b), (c), and (d) of the above-described method can be
modified in that, rather than exposing intact cells to the melanocyte
stimulating hormone, the ART polypeptide, or the substance,
20 membranes can be prepared from the cells and the membranes can be exposed to the melanocyte stimulating hormone, the ART polypeptide, or the substance. Such a modification utilizing membranes rather than intact cells in methods similar to that described above, although directed to the binding interactions of other ligands and receptors, is well known
25 in the art and is described in, *e.g.*, Hess *et al.*, 1992, Biochem. Biophys. Res. Comm. 184:260-268.

As a further modification of the above-described method,
RNA encoding the melanocortin receptor can be prepared as, *e.g.*, by *in vitro* transcription using a plasmid containing nucleotide sequences
30 encoding the melanocortin receptor under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into *Xenopus* oocytes in order to cause the expression of the melanocortin receptor in the oocytes. These oocytes then take the place of the cells in the above described method.

35 Once a substance has been identified as an inhibitor of the binding of the the ART polypeptide to the melanocortin receptor, that substance can be tested to determine whether it is also an agonist of the

WO 99/31508

PCT/US98/26457

25

melanocortin receptor. Such testing would involve exposing cells that express the melanocortin receptor to the substance, in the absence of the melanocyte stimulating hormone and the ART protein or ART polypeptides, and determining whether the melanocortin receptor is thereby activated by the substance. In this way, an inhibitor of the effect of ART protein on MC3R or MC4R can be identified that has no, or little, MC3R or MC4R agonist activity, but that relieves the inhibition of MC3R or MC4R receptor activity produced by ART protein. In a similar manner, it can be determined whether the substance is an antagonist of the melanocortin receptor.

The present invention also includes a method for determining whether a substance is an inhibitor of the binding of an ART polypeptide to a melanocortin receptor where the method comprises:

- (a) providing cells expressing a melanocortin receptor;
- (b) exposing the cells to an ART polypeptide in the presence and in the absence of the substance under conditions such that if the substance were not present, the ART polypeptide would bind to the melanocortin receptor;
- (c) measuring the amount of binding of the ART polypeptide to the melanocortin receptor in the presence and in the absence of the substance;

where a decrease in the amount of binding of the ART polypeptide to the melanocortin receptor in the presence as compared to the absence of the substance indicates that the substance is an inhibitor of the binding of the ART polypeptide to the melanocortin receptor.

In a particular embodiment, the cells expressing the melanocortin receptor are cells that naturally express the melanocortin receptor. In another embodiment, the cells expressing the melanocortin receptor do not naturally express the melanocortin receptor but have been transfected with an expression vector that directs the expression of the melanocortin receptor. Transfection is meant to include any method known in the art for the introduction of the the expression vector directing the expression of the melanocortin receptor into the cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct containing the melanocortin receptor, and electroporation.

WO 99/31508

PCT/US98/26457

26

In a particular embodiment, the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R). In a particular embodiment of the above-described method, the melanocortin receptor is not a *Xenopus* melanocortin receptor.

The cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor can be prokaryotic cells or eukaryotic cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: yeast cells, mammalian cells, bacterial cells, and insect cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: human cells, mouse cells, rat cells, bovine cells, porcine cells, hamster cells, and monkey cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171). In a particular embodiment, the cells are not *Xenopus* melanophore cells.

In a particular embodiment, the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.1-19 and 20. In particular embodiments of the above-described method, the ART polypeptide is used in a concentration of from 10^{-12} M to 10^{-7} M.

In particular embodiments of the above-described method, the method is practiced *in vitro* and the conditions are conditions that are typically used in the art for the study of protein-protein interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In particular embodiments of the above-described method, the method is practiced *in vitro* and the ART polypeptide is labeled, e.g.,

WO 99/31508

PCT/US98/26457

27

enzymatically, radioactively, or the like, and the amount of binding of the ART polypeptide to the melanocortin receptor is measured by determining the amount of label bound to the melanocortin receptor. The ART polypeptide will either be radioactively labeled by ^{32}P , ^{33}P , or ^{125}I (e.g., for c-ART-a or c-ART-c), or non-radioactively labeled (e.g., ART-AP, ART-luc, c-ART-AP or c-ART-luc). In the case of these latter ART polypeptides, the ART polypeptides can be detected by detecting the enzymatic activity of the alkaline phosphatase or luciferase moieties of the polypeptides.

Step (b) of the above-described method can be modified in that, rather than exposing the cells to an ART polypeptide in the presence and in the absence of the substance, membranes can be prepared from the cells and the membranes can be exposed to an ART polypeptide in the presence and in the absence of the substance. Such a modification utilizing membranes rather than cells in methods similar to that described above, although directed to the binding interactions of other ligands and receptors, is well known in the art and is described in, e.g., Hess *et al.*, 1992, Biochem. Biophys. Res. Comm. 184:260-268.

As a further modification of the above-described method, RNA encoding a melanocortin receptor can be prepared as, e.g., by *in vitro* transcription using a plasmid containing nucleotide sequences encoding a melanocortin receptor under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into *Xenopus* oocytes in order to cause the expression of the melanocortin receptor in the oocytes. These oocytes then take the place of the cells in the above described method.

Once a substance has been identified as an inhibitor of ART binding to a melanocortin receptor, that substance can be tested to determine whether it is also an agonist of the melanocortin receptor. Such testing would involve exposing cells that express the melanocortin receptor to the substance, in the absence of ART protein or ART polypeptides, and determining whether the melanocortin receptor is thereby activated by the substance. In this way, an inhibitor of ART protein binding to MC3R or MC4R may be identified that has no, or little, MC3R or MC4R agonist activity, but that relieves the inhibition of MC3R or MC4R receptor activity produced by ART protein.

WO 99/31508

PCT/US98/26457

28

The present invention also includes a method for determining whether a substance is an allosteric enhancer of the binding of an ART polypeptide to a melanocortin receptor where the method comprises:

- 5 (a) providing cells expressing a melanocortin receptor;
- (b) exposing the cells to an ART polypeptide in the presence and in the absence of the substance under conditions such that if the substance were not present, the ART polypeptide would bind to the melanocortin receptor;
- 10 (c) measuring the amount of binding of the ART polypeptide to the melanocortin receptor in the presence and in the absence of the substance;

 where an increase in the amount of binding of the ART polypeptide to the melanocortin receptor in the presence as compared to the absence of the substance indicates that the substance is an allosteric enhancer of the binding of the ART polypeptide to the melanocortin receptor.

 In a particular embodiment, the cells expressing the melanocortin receptor are cells that naturally express the melanocortin receptor. In another embodiment, the cells expressing the melanocortin receptor do not naturally express the melanocortin receptor but have been transfected with an expression vector that directs the expression of the melanocortin receptor. Transfection is meant to include any method known in the art for the introduction of the the expression vector directing the expression of the melanocortin receptor into the cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct containing the melanocortin receptor, and electroporation.

 In a particular embodiment, the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R). In a particular embodiment of the above-described method, the melanocortin receptor is not a *Xenopus* melanocortin receptor.

 The cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor can be prokaryotic cells or eukaryotic cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs

WO 99/31508

PCT/US98/26457

29

the expression of the melanocortin receptor are selected from the group consisting of: yeast cells, mammalian cells, bacterial cells, and insect cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: human cells, mouse cells, rat cells, bovine cells, porcine cells, hamster cells, and monkey cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171). In a particular embodiment, the cells are not *Xenopus* melanophore cells.

In a particular embodiment, the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.1-19 and 20. In particular embodiments of the above-described method, the ART polypeptide is used in a concentration of from 10^{-12} M to 10^{-7} M.

In particular embodiments of the above-described method, the method is practiced *in vitro* and the conditions are conditions that are typically used in the art for the study of protein-protein interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In particular embodiments of the above-described method, the method is practiced *in vitro* and the ART polypeptide is labeled, e.g., enzymatically, radioactively, or the like, and the amount of binding of the ART polypeptide to the melanocortin receptor is measured by determining the amount of label bound to the melanocortin receptor.

Step (b) of the above-described method can be modified in that, rather than exposing the cells to an ART polypeptide in the presence and in the absence of the substance, membranes can be prepared from the cells and the membranes can be exposed to an ART polypeptide in the presence and in the absence of the substance. Such a modification utilizing membranes rather than cells in methods similar

WO 99/31508

PCT/US98/26457

30

to that described above, although directed to the binding interactions of other ligands and receptors, is well known in the art and is described in, *e.g.*, Hess *et al.*, 1992, Biochem. Biophys. Res. Comm. 184:260-268.

As a further modification of the above-described method,
5 RNA encoding a melanocortin receptor can be prepared as, *e.g.*, by *in vitro* transcription using a plasmid containing nucleotide sequences encoding a melanocortin receptor under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into *Xenopus* oocytes in order to cause the expression of the melanocortin receptor in the oocytes.
10 These oocytes then take the place of the cells in the above described method.

Melanocortin receptors are G-protein coupled receptors that stimulate G_s, leading to the production of cAMP (Cone *et al.*, 1996, Recent Prog. Hormone Res. 51:287-318). Thus, the ART polypeptides of
15 the present invention can be used in a method for determining whether a substance is a functional inhibitor of the antagonistic effect of an ART polypeptide on a melanocortin receptor where the method comprises:
(a) providing cells expressing a melanocortin receptor;
(b) exposing the cells to a melanocyte stimulating
20 hormone, thereby activating the melanocortin receptor and leading to the production of cAMP mediated by the melanocortin receptor;
(c) exposing the cells to an ART polypeptide in the presence and in the absence of the substance under conditions such that if the substance were not present, the ART polypeptide would inhibit the
25 production of cAMP mediated by the melanocortin receptor;
(d) measuring the amount of cAMP produced the presence and in the absence of the substance;
where an increase in the amount of cAMP produced in the presence as compared to the absence of the substance indicates that the
30 substance is a functional inhibitor of the antagonistic effect of the ART polypeptide on the melanocortin receptor.

In a particular embodiment, the cells expressing the melanocortin receptor are cells that naturally express the melanocortin receptor. In another embodiment, the cells expressing the melanocortin
35 receptor do not naturally express the melanocortin receptor but have been transfected with an expression vector that directs the expression of the melanocortin receptor. Transfection is meant to include any method

WO 99/31508

PCT/US98/26457

31

known in the art for the introduction of the the expression vector directing the expression of the melanocortin receptor into the cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct containing the melanocortin receptor, and electroporation.

5 In a particular embodiment, the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R). In a particular embodiment of the above-described method, the melanocortin receptor is
10 not a *Xenopus* melanocortin receptor.

The cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor can be prokaryotic cells or eukaryotic cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs
15 the expression of the melanocortin receptor are selected from the group consisting of: yeast cells, mammalian cells, bacterial cells, and insect cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: human cells, mouse
20 cells, rat cells, bovine cells, porcine cells, hamster cells, and monkey cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group consisting of: L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573),
25 Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171). In a particular embodiment, the cells are not *Xenopus* melanophore cells.

30 In a particular embodiment, the melanocyte stimulating hormone is selected from the group consisting of: α -melanocyte stimulating hormone, β -melanocyte stimulating hormone, and γ -melanocyte stimulating hormone.

In a particular embodiment, the ART polypeptide has an
35 amino acid sequence selected from the group consisting of: SEQ.ID.NO.s.1-19 and 20.

WO 99/31508

PCT/US98/26457

32

In particular embodiments of the above-described method, the method is practiced *in vitro* and the conditions are conditions that are typically used in the art for the study of protein-protein interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

Once a substance has been identified as a functional inhibitor of the antagonistic effect of an ART polypeptide on a melanocortin receptor, that substance can be tested to determine whether it is also an agonist of the melanocortin receptor. Such testing would involve exposing cells that express the melanocortin receptor to the substance, in the absence of ART protein or ART polypeptides, and determining whether the melanocortin receptor is thereby activated by the substance. In this way, an inhibitor of ART protein binding to MC3R or MC4R may be developed that has no, or little, MC3R or MC4R agonist activity, but that relieves the inhibition of MC3R or MC4R receptor activity produced by ART protein. In a similar manner, it can be determined whether the substance is an antagonist of the melanocortin receptor.

The ART polypeptides of the present invention can also be used in a method of determining whether a substance is an inhibitor of the effect of an ART polypeptide that makes use of an assay utilizing a *Xenopus* melanophore cell line (see, *e.g.*, Quillan *et al.*, 1995, Proc. Natl. Acad. Sci. USA 92:2894; Potenza & Lerner, 1992, Pigment Cell Res. 5:372; Ollman *et al.*, 1997, Science 278:135-138). Such a method comprises:

- (a) providing a *Xenopus* melanophore cell line;
- (b) exposing the *Xenopus* melanophore cell line to a chosen concentration of a melanocyte stimulating hormone in the absence of the ART polypeptide and in the absence of the substance and measuring the amount of pigment dispersion to obtain a first value for pigment dispersion;
- (c) exposing the *Xenopus* melanophore cell line to the chosen concentration of α -melanocyte stimulating hormone in the presence of the ART polypeptide and in the absence of the substance and measuring the amount of pigment dispersion to obtain a second value for pigment dispersion where the second value for pigment dispersion

WO 99/31508

PCT/US98/26457

33

indicates that less pigment has been dispersed as compared to the first value for pigment dispersion;

(d) exposing the *Xenopus* melanophore cell line to the chosen concentration of α -melanocyte stimulating hormone in the presence of the ART polypeptide and in the presence of the substance and measuring the amount of pigment dispersion to obtain a third value for pigment dispersion;

where if the third value for pigment dispersion indicates that more pigment has been dispersed as compared with the second value, then the substance is an inhibitor of the effect of the ART polypeptide.

In a particular embodiment, the melanocyte stimulating hormone is selected from the group consisting of: α -melanocyte stimulating hormone, β -melanocyte stimulating hormone, and γ -melanocyte stimulating hormone.

In a particular embodiment, the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.s.1-19 and 20.

In particular embodiments of the above-described method, the conditions are conditions that are typically used in the art for the study of protein-protein interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

Once a substance has been identified as an inhibitor of the effect of an ART polypeptide, that substance can be tested to determine whether it is also an agonist of the *Xenopus* melanocortin receptor. Such testing would involve exposing melanophore cells that express the *Xenopus* melanocortin receptor to the substance, in the absence of ART protein or ART polypeptides, and determining whether the melanocortin receptor is thereby activated by the substance. In this way, an inhibitor of ART protein binding to the *Xenopus* melanocortin receptor can be identified that may be used as a lead to develop ART binding inhibitors for human MC3R or MC4R that have no, or little, MC3R or MC4R agonist activity, but that relieve the inhibition of MC3R or MC4R receptor activity produced by ART protein. In a similar manner, it can be determined whether the substance is an antagonist of the melanocortin receptor.

WO 99/31508

PCT/US98/26457

34

The present invention includes a method of determining whether a substance is an inhibitor of the binding of an ART polypeptide to a melanocortin receptor comprising:

- (a) providing cells expressing the melanocortin receptor;
- 5 (b) exposing the cells to a chosen concentration of the melanocyte stimulating hormone and a chosen concentration of the ART polypeptide in the presence and in the absence of the substance and measuring the amount of melanocyte stimulating hormone binding to the cells in the presence and in the absence of the substance;
- 10 where an increase in the amount of melanocyte stimulating hormone binding in the presence of the substance indicates that the substance is an inhibitor of the binding of an ART polypeptide to a melanocortin receptor.

In a particular embodiment, the cells expressing the melanocortin receptor are cells that naturally express the melanocortin receptor. In another embodiment, the cells expressing the melanocortin receptor do not naturally express the melanocortin receptor but have been transfected with an expression vector that directs the expression of the melanocortin receptor. Transfection is meant to include any method
15 known in the art for the introduction of the the expression vector directing the expression of the melanocortin receptor into the cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct containing the melanocortin receptor, and electroporation.

25 In a particular embodiment, the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R). In a particular embodiment of the above-described method, the melanocortin receptor is not a *Xenopus* melanocortin receptor.

30 The cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor can be prokaryotic cells or eukaryotic cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin receptor are selected from the group
35 consisting of: yeast cells, mammalian cells, bacterial cells, and insect cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin

WO 99/31508

PCT/US98/26457

35

receptor are selected from the group consisting of: human cells, mouse cells, rat cells, bovine cells, porcine cells, hamster cells, and monkey cells. In a particular embodiment, the cells that have been transfected with an expression vector that directs the expression of the melanocortin
5 receptor are selected from the group consisting of: L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 cells (ATCC CRL 1573), Raji cells (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I
10 (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171). In a particular embodiment, the cells are not *Xenopus* melanophore cells.

In a particular embodiment, the melanocyte stimulating hormone is selected from the group consisting of: α -melanocyte
15 stimulating hormone, β -melanocyte stimulating hormone, and γ -melanocyte stimulating hormone.

In a particular embodiment, the ART polypeptide has an amino acid sequence selected from the group consisting of:
SEQ.ID.NO.s.1-19 and 20.

20 In particular embodiments of the above-described method, the method is practiced *in vitro* and the conditions under which the method is practiced are conditions that are typically used in the art for the study of protein-protein interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as
25 PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In particular embodiments of the above-described method, the chosen concentration of the melanocyte stimulating hormone is from 0.05 nM to 2.0 nM, preferably from 0.1 nM to 1.0 nM, and more preferably from 0.2 nM to 0.5 nM.

30 In particular embodiments of the above-described method, the chosen concentration of the ART polypeptide is from 10⁻¹² M to 10⁻⁷ M.

In particular embodiments of the above-described method, the method is practiced *in vitro* and the melanocyte stimulating
35 hormone is labeled, *e.g.*, enzymatically, radioactively, or the like, and the amount of binding of the melanocyte stimulating hormone to the

WO 99/31508

PCT/US98/26457

36

melanocortin receptor is measured by determining the amount of label bound to the cells containing the melanocortin receptor.

Step (b) of the above-described method can be modified in that, rather than exposing intact cells to the melanocyte stimulating hormone, the ART polypeptide, or the substance, membranes can be prepared from the cells and the membranes can be exposed to the melanocyte stimulating hormone, the ART polypeptide, or the substance. Such a modification utilizing membranes rather than intact cells in methods similar to that described above, although directed to the binding interactions of other ligands and receptors, is well known in the art and is described in, *e.g.*, Hess *et al*, 1992, *Biochem. Biophys. Res. Comm.* 184:260-268.

As a further modification of the above-described method, RNA encoding the melanocortin receptor can be prepared as, *e.g.*, by *in vitro* transcription using a plasmid containing nucleotide sequences encoding the melanocortin receptor under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into *Xenopus* oocytes in order to cause the expression of the melanocortin receptor in the oocytes. These oocytes then take the place of the cells in the above described method.

Once a substance has been identified as an inhibitor of the binding of the the ART polypeptide to the melanocortin receptor, that substance can be tested to determine whether it is also an agonist of the melanocortin receptor. Such testing would involve exposing cells that express the melanocortin receptor to the substance, in the absence of the melanocyte stimulating hormone and the ART protein or ART polypeptides, and determining whether the melanocortin receptor is thereby activated by the substance. In this way, an inhibitor of the effect of ART protein on MC3R or MC4R can be identified that has no, or little, MC3R or MC4R agonist activity, but that relieves the inhibition of MC3R or MC4R receptor activity produced by ART protein. In a similar manner, it can be determined whether the substance is an antagonist of the melanocortin receptor.

Compared to full-length ART protein, the ART polypeptides of the present invention are smaller, and therefore easier to produce and less likely to be degraded. With respect to such embodiments of the invention as, *e.g.*, c-ART-b, the non-ART protein amino acid sequences

WO 99/31508

PCT/US98/26457

37

added to the C-terminus of the ART sequences do not impair binding or functional activity, and allow ^{32}P or ^{33}P labeling without the need to label the ART sequence. Fusion polypeptides such as, *e.g.*, ART-AP or ART-luc, allow the use of non-radioactive methods to detect ART polypeptides in binding assays.

That the ART polypeptides of the present invention having amino acid sequences from non-ART proteins at their C-terminus are functional is surprising. The C-terminus of ART protein is homologous to the C-terminus of the agouti protein, both the ART protein and the agouti protein having a characteristic pattern of cysteine residues in this region. A similar pattern of cysteine residues has been found in certain ion channel blockers from spider and snail toxins. This pattern of cysteines has been proposed to result in the formation of specific disulfide bridges that constrain the toxins into a characteristic three-dimensional structure that is responsible for the toxins' biological activity (Kim *et al.*, 1995, J. Mol. Biol. 250:659-671; hereinafter "Kim"). While the extreme C-terminal amino acids of the toxin studied by Kim were not part of this three-dimensional structure, these extreme C-terminal amino acids were nevertheless "crucially important," since altering them resulted in a loss of activity. See page 665, right column of Kim: "These results suggest that the C-terminal segment of ω -AGA-IVA is crucially important for its blocking action on the P-type calcium channel expressed in rat cerebellar Purkinje cells." Thus, one would have expected that altering the C-terminus of the ART protein, *e.g.*, by linking it to sequences from a non-ART protein, would have resulted in an ART fusion polypeptide which would lack the activity of the full-length ART protein, or at least show substantially less activity. The present invention demonstrates that this is not so.

The following non-limiting examples are presented to better illustrate the invention.

WO 99/31508

PCT/US98/26457

38

EXAMPLE 1

Production of a construct expressing c-ART-b

The expression plasmid for c-ART-b was constructed by modifying the ART expression plasmid which was generated by inserting the ART cDNA into the EcoRI and BamHI sites of pcDNA3.1-Myc-His-A (Fong *et al.*, 1997, Biochem. Biophys. Res. Comm. 237:629-631; hereinafter "Fong"). The c-ART-b sequence differs from that of the recombinant ART as described by Fong in that residues 27-75 were deleted from ART. To accomplish that, a first PCR was carried out using the ART expression plasmid as template and two oligos (GGGCTCGGCGGTCTGCAGGGCCAAGCCCATCTGGGC (SEQ.ID.NO.:21); and the T7 primer TAATACGACTCACTATAGGG (SEQ.ID.NO.:22)) to amplify the DNA fragment encoding ART residues 1-26 followed immediately by residues 76-81. A second PCR was carried out using the ART expression plasmid as template and two other oligos (CTGCAGGACCGCGAGCCC (SEQ.ID.NO.:23); and the pcDNA3.1A primer GTCGACGGCGCTATTTCAG (SEQ.ID.NO.:24)) to amplify the DNA fragment encoding ART residues 76-132. A third PCR was then carried out using the first and the second PCR products as template and two oligos (the T7 primer and the pcDNA3.1A primer) to amplify the c-ART-b cDNA. The final PCR product was cleaved by the restriction enzymes EcoRI and BamHI, and ligated to the pcDNA3.1-Myc-His-A vector similarly cleaved by EcoRI and BamHI. The thrombin site sequence was based on the thrombin site in pET-34b (Novagen, Milwaukee, WI). The Myc epitope sequence and hexahistidine sequence were contained within the pcDNA3.1-Myc-His-A vector (Invitrogen, Carlsbad, CA).

EXAMPLE 2

30 Expression of c-ART-b

COS-7 cells in T-175 flasks were transiently transfected with the c-ART-b expression plasmid (24 µg) by lipofectamine (Gibco), and grown in Opti-mem media (Gibco) supplemented with 1% fetal bovine

WO 99/31508

PCT/US98/26457

39

serum. Two days after transfection, culture media were collected, centrifuged to remove residual cells, concentrated about 100-fold in Centriprep-3 (Amicon) and stored at 4 °C in the presence of 2.5 mM EGTA, 4 mg/ml leupeptin, and 0.01 mM phosphoramidon. After
5 determination of the concentration of c-ART-b, NaN₃ was added to 0.02%. Determination of the concentration of c-ART-b, which contains the Myc sequence, was based on an ELISA standard curve. Briefly, the microtiter plate was coated with 0.2 µg of a Myc peptide (human c-Myc 408-439) overnight, washed, blocked, and followed by incubation with
10 anti-Myc mAb-HRP conjugates (Invitrogen) in the presence of varying concentrations of the free Myc peptide for 2 hours. The bound mAb-HRP was detected using a colorimetric substrate tetramethylbenzidine (BioRad). For c-ART-b concentration determination, a c-ART-b sample replaced the free Myc peptide.

15

EXAMPLE 3

Binding of c-ART-b to MC3R and MC4R

Binding assays were done in the same manner as described in Fong *et al.*, 1997, Biochem. Biophys. Res. Comm. 237:629-631. Binding
20 assays were carried out using membranes prepared from L cells or CHO cells stably expressing human MC3R, MC4R or MC5R. The binding assay mixture contained 0.2 nM of ¹²⁵I-[Tyr²][Nle⁴, D-Phe⁷] α-melanocyte stimulating hormone (¹²⁵I -NDP-α-MSH), varying concentrations of c-ART-b or full-length ART protein, and an
25 appropriate amount of membranes so that the total bound radioligand was less than 10% of the added radioligand. The above mixture in binding buffer (50 mM Tris, 2 mM CaCl₂, 1 mM MgCl₂, 5 mM KCl, pH 7.2) was incubated at room temperature for 2 hours, followed by filtration through GFC paper. The bound ligand was quantitated in a γ
30 counter. IC₅₀ values were calculated as previously described (Fong *et al.*, 1996, Mol. Pharmacol. 50:1605-1611). The results are shown in Figure 2. From Figure 2 it can be seen that c-ART-b inhibits the binding of ¹²⁵I-NDP-α-MSH to MC3R.

A similar experiment was done to determine whether c-
35 ART-b inhibits the binding of ¹²⁵I-labeled NDP-α-MSH to MC4R. The

WO 99/31508

PCT/US98/26457

40

results are shown in Figure 3. From Figure 3 it can be seen that c-ART-b inhibits the binding of ^{125}I -NDP- α -MSH to hMC4R.

Similar experiments were performed with full-length human ART protein. Similar experiments were also performed with full-length ART protein and with c-ART-b for the melanocortin-5 receptor (MC5R). From these experiments, from the results shown in Figures 2 and 3, and from similar experiments, the following IC_{50} values for the inhibition of ^{125}I -labeled NDP- α -MSH to MC3R, MC4R, and MC5R by full-length ART protein and by c-ART-b can be determined.

Table 1

	hMC3R	hMC4R	hMC5R
full length ART	1.0 \pm 0.4 (4)	0.5 \pm 0.1 (3)	>40
c-ART-b	1.9 \pm 1.0 (2)	1.4 \pm 0.1 (2)	not done

The IC_{50} values shown in Table 1 are given in nM. The numbers in parentheses represent the number of experiments run. The results shown in Table 1 indicate that, surprisingly, c-ART-b, although missing a significant amount of sequence from the N-terminus of the ART protein, is essentially functionally equivalent to full length ART protein. In addition, c-ART-b is functional despite having a significant amount of non-ART sequences at its C-terminus (a thrombin site, a myc epitope, and a hexahistidine tag).

EXAMPLE 4

Functional assay for the binding of c-ART-b to MC3R and MC4R

The ability of c-ART-b to inhibit the production of cAMP by α -melanocyte stimulating hormone acting through MC3R or MC4R can be demonstrated by preincubating L Cells stably expressing human MC3R or MC4R with c-ART-b for 10 minutes, followed by incubation with 20 nM α -melanocyte stimulating hormone for 45 minutes. The incubation buffer also contains Earle's balanced salt solution, 10 mM

WO 99/31508

PCT/US98/26457

41

HEPES, 5 mM MgCl₂, 1 mg/ml BSA and 0.5 mM IBMX. Following the incubation, cells are lysed by boiling for 4 minutes. Intracellular cAMP concentration is measured by RIA (Huang *et al.*, 1997, J. Receptor Signal Transduc. Res. 17:599-607) using anti-cAMP antibody and ¹²⁵I-cAMP as modified in the scintillation proximity assay format (Amersham).

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

15

WO 99/31508

PCT/US98/26457

42

WHAT IS CLAIMED:

1. A fusion protein having an amino acid sequence from the ART protein fused at its carboxy terminus to one or more amino acid sequences not derived from the ART protein, where the amino acid sequence from the ART protein is selected from the group consisting of: SEQ.ID.NOs.:6-8 and 9.
2. The fusion protein of claim 1 having an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.:1-5, 10-19, and 20.
3. The fusion protein of claim 2 having the amino acid sequence of SEQ.ID.NO.:2.
4. An ART polypeptide having an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.:6-8 and 9.
5. A DNA sequence encoding the fusion protein of claim 1.
6. A method of determining whether a substance is an inhibitor of the binding of an ART polypeptide to a melanocortin receptor where the method comprises:
 - (a) providing cells expressing the melanocortin receptor;
 - (b) exposing the cells to a chosen concentration of the melanocyte stimulating hormone in the absence of the ART polypeptide and in the absence of the substance and measuring the amount of melanocyte stimulating hormone binding to the cells to obtain a first value for melanocyte stimulating hormone binding;
 - (c) exposing the cells to the chosen concentration of melanocyte stimulating hormone in the presence of a chosen concentration of the ART polypeptide and in the absence of the substance and measuring the amount of melanocyte stimulating hormone binding to obtain a second value for melanocyte stimulating hormone binding where the second value for melanocyte stimulating hormone binding indicates that less melanocyte stimulating hormone binding has

WO 99/31508

PCT/US98/26457

43

occurred as compared to the first value for melanocyte stimulating hormone binding;

- (d) exposing the cells to the chosen concentration of melanocyte stimulating hormone in the presence of the chosen
5 concentration of ART polypeptide and in the presence of the substance and measuring the amount of melanocyte stimulating hormone binding to obtain a third value for melanocyte stimulating hormone binding;

where, if the third value for melanocyte stimulating hormone binding is greater than the second value, then the substance is
10 an inhibitor of the binding of the ART polypeptide to the melanocortin receptor;

where the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.:1-19 and 20.

- 15 7. The method of claim 6 where the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R).

- 20 8. A method for determining whether a substance is an inhibitor of the binding of an ART polypeptide to a melanocortin receptor where the method comprises:

- (a) providing cells expressing a melanocortin receptor;
(b) exposing the cells to an ART polypeptide in the
presence and in the absence of the substance under conditions such that
25 if the substance were not present, the ART polypeptide would bind to the melanocortin receptor;

- (c) measuring the amount of binding of the ART polypeptide to the melanocortin receptor in the presence and in the absence of the substance;

- 30 where a decrease in the amount of binding of the ART polypeptide to the melanocortin receptor in the presence as compared to the absence of the substance indicates that the substance is an inhibitor of the binding of the ART polypeptide to the melanocortin receptor;

- where the ART polypeptide has an amino acid sequence
35 selected from the group consisting of: SEQ.ID.NOs.:1-19 and 20.

WO 99/31508

PCT/US98/26457

44

9. The method of claim 8 where the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R).

5 10. A method for determining whether a substance is an allosteric enhancer of the binding of an ART polypeptide to a melanocortin receptor where the method comprises:

(a) providing cells expressing a melanocortin receptor;

10 (b) exposing the cells to an ART polypeptide in the presence and in the absence of the substance under conditions such that if the substance were not present, the ART polypeptide would bind to the melanocortin receptor;

(c) measuring the amount of binding of the ART polypeptide to the melanocortin receptor in the presence and in the
15 absence of the substance;

where an increase in the amount of binding of the ART polypeptide to the melanocortin receptor in the presence as compared to the absence of the substance indicates that the substance is an allosteric enhancer of the binding of the ART polypeptide to the melanocortin
20 receptor;

where the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.:1-19 and 20.

11. The method of claim 10 where the melanocortin
25 receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R).

12. A method for determining whether a substance is a functional inhibitor of the antagonistic effect of an ART polypeptide on a melanocortin receptor where the method comprises:

30 (a) providing cells expressing a melanocortin receptor;

(b) exposing the cells to a melanocyte stimulating hormone selected from the group consisting of: α -melanocyte stimulating hormone, β -melanocyte stimulating hormone, and γ -

35 melanocyte stimulating hormone, in order to activate the melanocortin receptor, leading to the production of cAMP;

WO 99/31508

PCT/US98/26457

45

(c) exposing the cells to an ART polypeptide in the presence and in the absence of the substance under conditions such that if the substance were not present, the ART polypeptide would inhibit the production of cAMP mediated by the melanocortin receptor;

5 (d) measuring the amount of cAMP produced the presence and in the absence of the substance;

where an increase in the amount of cAMP produced in the presence as compared to the absence of the substance indicates that the substance is a functional inhibitor of the antagonistic effect of the ART polypeptide on the melanocortin receptor;

10 where the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.:1-19 and 20.

13. The method of claim 12 where the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R).

14. A method of determining whether a substance is an inhibitor of the effect of an ART polypeptide comprising:

20 (a) providing a *Xenopus* melanophore cell line;

(b) exposing the *Xenopus* melanophore cell line to a chosen concentration of α -melanocyte stimulating hormone in the absence of the ART polypeptide and in the absence of the substance and measuring the amount of pigment dispersion to obtain a first value for pigment dispersion;

25 (c) exposing the *Xenopus* melanophore cell line to the chosen concentration of α -melanocyte stimulating hormone in the presence of the ART polypeptide and in the absence of the substance and measuring the amount of pigment dispersion to obtain a second value for pigment dispersion where the second value for pigment dispersion indicates that less pigment has been dispersed as compared to the first value for pigment dispersion;

30 (d) exposing the *Xenopus* melanophore cell line to the chosen concentration of α -melanocyte stimulating hormone in the presence of the ART polypeptide and in the presence of the substance and measuring the amount of pigment dispersion to obtain a third value for pigment dispersion;

WO 99/31508

PCT/US98/26457

46

where if the third value for pigment dispersion indicates that more pigment has been dispersed as compared with the second value, then the substance is an inhibitor of the effect of the ART polypeptide;

5 where the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.:1-19 and 20.

10 15. A method of determining whether a substance is an inhibitor of the binding of an ART polypeptide to a melanocortin receptor comprising:

 (a) providing cells expressing the melanocortin receptor;
 (b) exposing the cells to a chosen concentration of the melanocyte stimulating hormone and a chosen concentration of the ART polypeptide in the presence and in the absence of the substance and
15 measuring the amount of melanocyte stimulating hormone binding to the cells in the presence and in the absence of the substance;

 where an increase in the amount of melanocyte stimulating hormone binding in the presence of the substance indicates that the substance is an inhibitor of the binding of an ART polypeptide to a
20 melanocortin receptor;

 where the ART polypeptide has an amino acid sequence selected from the group consisting of: SEQ.ID.NOs.:1-19 and 20.


25 16. The method of claim 15 where the melanocortin receptor is selected from the group consisting of: the melanocortin-3 receptor (MC3R) and the melanocortin-4 receptor (MC4R).

WO 99/31508

PCT/US98/26457

1 / 3

FIGURE 1




WO 99/31508

PCT/US98/26457

2 / 3

FIGURE 2




CPM

WO 99/31508

PCT/US98/26457

3 / 3

FIGURE 3



CPM

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26457

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :G01N 33/53, 33/566; C07K 14/435, 19/00; C12N 15/12

US CL :530/300, 350; 536/23.4; 436/501

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300, 350; 536/23.4; 436/501

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS; DIALOG - Biotech Files; GenEMBL sequence databases

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KWON, H. Y. et al. Molecular structure and chromosomal mapping of the human homolog of the agouti gene. Proceedings of the National Academy of Sciences, USA. October 1994, Vol. 91, pages 9760-9764, see entire document.	1-16
A	STARK, M. J. R. et al. The killer toxin of Kluyveromyces lactis: characterization of the toxin subunits and identification of the genes which encode them. The EMBO Journal. 1986, Vol. 5, No. 3, pages 1995-2002, see entire document.	1-16



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*g* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 APRIL 1999

Date of mailing of the international search report

23 APR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MP WOODWARD

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26457

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHUTTER, J. R. et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes and Development. 1997, Vol. 11, pages 593-602, see entire document.	1-16
Y,P	US 5,766,877 (STARK et al) 16 June 1998, columns 1-36, see entire document.	1-16

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.